Several studies in animal models have shown that GLP-1 receptor agonists may ameliorate motor and cognitive symptoms in Parkinson’s disease (PD) or AD [64], thus slowing the development of neurodegeneration. The gene discussed is GLP1R; the disease is Parkinson disease.